SCHEMBL20468837

SCHEMBL20468837

Cc1cc(N2CCC3(CN(C(=O)OC(C)(C)C)C3)C2)cc(C)n1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 1/20 0.49
▸ ACACB O00763 6/20 0.48
▸ SCD5 Q86SK9 1/20 0.43
▸ OGA O60502 3/20 0.42
▸ EGLN2 Q96KS0 1/20 0.42
▸ GPR119 Q8TDV5 1/20 0.42
▸ PARP1 P09874 1/20 0.42
▸ GPR183 P32249 1/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ EIF2AK4 Q9P2K8 1/20 0.41
▸ RET P07949 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20469135 0.94 CYP11B2 (0.53) CYP11B2ACACBSCD5OGAPARP1
SCHEMBL21711129 0.94 CYP11B2 (0.53) CYP11B2ACACBSCD5OGAPARP1
SCHEMBL20468832 0.93 CYP11B2 (0.52) CYP11B2ACACBSCD5EGLN2GPR119
SCHEMBL20510354 0.90 EGLN2 (0.49) CYP11B2ACACBSCD5EGLN2GPR119
SCHEMBL20469064 0.86 OGA (0.50) CYP11B2ACACBSCD5OGAGPR183
SCHEMBL20468835 0.85 ACACB (0.49) CYP11B2ACACBSCD5OGAPARP1
SCHEMBL20469019 0.85 OGA (0.51) CYP11B2ACACBSCD5OGAGPR119
SCHEMBL30328000 0.83 CYP11B2 (0.46) CYP11B2ACACBSCD5OGAGPR119
SCHEMBL20469071 0.83 CYP11B2 (0.46) CYP11B2ACACBSCD5OGAPARP1
SCHEMBL38662223 0.81 CYP3A4 (0.62) CYP11B2CYP3A4CYP2C9CYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048267-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2020-02-13 — — US disclosed
WO-2018141984-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2018-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048267-A1 OGA INHIBITOR COMPOUNDS OGA, OGT, GRN CYP11B2 4635/4885ACACB 639/4885SCD5 1478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback